Neuren Pharmaceuticals (ASX:NEU): Royalty Growth, Clinical Trials and Interim Results

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Neuren Pharmaceuticals (ASX:NEU): Royalty Growth, Clinical Trials and Interim Results

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Neuren Pharmaceuticals (ASX:NEU) reported H1 2026 revenue of AUD 42.7 million.
H1 2026 profit after tax was AUD 4.9 million, compared with AUD 15.0 million a year earlier.
DAYBUE royalty income reached USD 23.3 million in H1 2026, up 29% in US-dollar terms.
The company declared its first interim dividend of AUD 0.15 per share, fully franked.

Neuren Pharmaceuticals Limited develops treatments for serious neurological conditions associated with genetic disorders and brain injury, including therapies for Rett syndrome and Phelan-McDermid syndrome. The Melbourne-based biopharmaceutical company reported increased royalty receipts from licensed treatment DAYBUE while advancing its NNZ-2591 clinical program in 2026. At the time of writing on 22 October 2026, Neuren Pharmaceuticals (ASX:NEU) was quoted at AUD 19.57, down 0.66% during the trading session.

Company Business

Neuren Pharmaceuticals (ASX:NEU) operates through two principal drug-development and licensing activities. Its approved trofinetide product, marketed as DAYBUE, is licensed globally to Acadia Pharmaceuticals. Neuren receives royalties on applicable sales and has rights to certain contractual milestone payments. Commercialisation therefore depends on the licensee’s execution, product uptake and territory-specific regulatory decisions.

Its separately developed candidate NNZ-2591, also known as ercanetide, is being investigated for neurodevelopmental conditions. The Koala Phase 3 trial is evaluating the treatment in children with Phelan-McDermid syndrome. The broader pipeline includes Pitt Hopkins syndrome and hypoxic-ischaemic encephalopathy. These are investigational programs; clinical success and marketing authorisation have not been established.

Recent Development

In August 2026, Neuren Pharmaceuticals (ASX:NEU) announced a dividend program tied to the after-tax portion of royalty income, after corporate and administrative expenses. Directors declared a fully franked AUD 0.15 interim dividend per share, with payment scheduled for 7 October 2026. The declaration reflected a stated payout ratio of 90% of the H1 2026 available pool, rather than a commitment to a fixed dividend amount.

The company also reported that its partner’s DAYBUE net sales increased to USD 226 million in H1 2026, up 25% year on year. The powder formulation, DAYBUE STIX, expanded access in the US during the year. Separately, Neuren continued enrolment and development activities for the Koala Phase 3 program, a major component of its research expenditure.

Financial Performance and Sector Context

Neuren Pharmaceuticals (ASX:NEU) recorded AUD 42.746 million of revenue from ordinary activities in H1 2026, an 8% increase from AUD 39.723 million in H1 2025. Net profit after tax decreased to AUD 4.852 million from AUD 15.031 million. Royalty income was USD 23.3 million, equivalent to AUD 33.2 million, representing growth of 29% in US dollars and 17% in Australian dollars.

Research and development spending rose to AUD 27.4 million as the Koala study progressed. Cash and short-term investments stood at AUD 286.5 million on 30 June 2026, compared with AUD 296.1 million at the end of December 2025. Net operating cash inflow was AUD 8.0 million, against AUD 128.3 million in H1 2025; the earlier comparison included substantial non-recurring licensing-related receipts.

The partner increased its 2026 DAYBUE net-sales guidance to USD 480–510 million. Based on this range, Neuren indicated royalty income for 2026 of approximately USD 53–56 million. Pharmaceutical earnings remain sensitive to clinical development expenditure, licensing arrangements, reimbursement, regulatory approvals and movements between the US and Australian dollars.

Risks to Consider

Neuren Pharmaceuticals (ASX:NEU) faces clinical trial uncertainty because NNZ-2591 must satisfy efficacy and safety requirements before any potential marketing approval. Patient recruitment, study timelines and expenditure may differ from management plans. The royalty business is exposed to a single commercialised treatment, its licensee’s performance, reimbursement arrangements and changes in prescribing demand. Currency movements also affect Australian-dollar royalty receipts.

What to Watch Next

Relevant milestones include further recruitment and trial execution under the Koala Phase 3 program, development decisions for additional NNZ-2591 indications, and updates on DAYBUE prescription volumes and sales. Neuren Pharmaceuticals (ASX:NEU) has also identified regulatory and commercial progress in Europe and the partner’s Japanese clinical program as areas for monitoring. Subsequent company releases will clarify whether previously indicated timelines are maintained.

Key Insights

Neuren’s H1 2026 results combined higher recurring royalty income with lower statutory profit, reflecting the impact of increased research spending and comparisons with prior non-recurring receipts. Its cash holdings support ongoing clinical activity, while the first interim dividend established a new distribution framework. The central measurable developments are DAYBUE sales, NNZ-2591 clinical progress and updated financial disclosures.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.